JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1-Reference-Cited by-同舟云学术

JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1

Published:2019-03-14 Issue:6 Volume:69 Page:2349-2363
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Zeuzem Stefan¹,Bourgeois Stefan²,Greenbloom Susan³,Buti Maria⁴,Aghemo Alessio⁵,Lampertico Pietro⁶^ORCID,Janczewska Ewa⁷⁸,Lim Seng Gee⁹,Moreno Christophe¹⁰,Buggisch Peter¹¹,Tam Edward¹²,Corbett Chris¹³,Willems Wouter¹³,Vijgen Leen¹³,Fevery Bart¹³,Ouwerkerk-Mahadevan Sivi¹³,Ackaert Oliver¹³,Beumont Maria¹³,Kalmeijer Ronald¹⁴,Sinha Rekha¹⁴,Biermer Michael¹³,

Affiliation:

1. Department of Medicine; J.W. Goethe University Hospital; Frankfurt am Main Germany

2. Department of Gastroenterology and Hepatology; ZNA Antwerp; Antwerp Belgium

3. Toronto Digestive Disease Associates, Inc.; Vaughan ON Canada

4. Hospital Vall d’Hebron and Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd); Barcelona Spain

5. Humanitas University and Research Hospital; Rozzano Italy

6. CRC “AM e A Migliavacca,” Division of Gastroenterology and Hepatology; Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Università di Milano; Milan Italy

7. Outpatients Clinic for Hepatology, ID Clinic; Myslowice Poland

8. Medical University of Silesia, School of Public Health in Bytom, Department of Basic Medical Sciences; Bytom Poland

9. Division of Gastroenterology and Hepatology, Department of Medicine; Yong Loo Lin School of Medicine, National University Health System; Singapore

10. CUB Hôpital Erasme, Université Libre de Bruxelles; Brussels Belgium

11. Institute for Interdisciplinary Medicine; Hamburg Germany

12. LAIR Centre; Vancouver BC Canada

13. Janssen Research & Development, Janssen Pharmaceutica NV; Beerse Belgium

14. Janssen Research & Development, LLC; Titusville NJ

Funder

Janssen Research and Development

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hep.30527/fullpdf

Reference36 articles.

1. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study;Polaris Observatory HCV Collaborators;Lancet Gastroenterol Hepatol,2017

2. World Health Organization Hepatitis C fact sheet 164 http://www.who.int/mediacentre/factsheets/fs164/en/

3. Increasing success and evolving barriers in the hepatitis C cascade of care during the direct acting antiviral era;Zuckerman;PLoS One,2018

4. Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response;Simmons;Clin Infect Dis,2015

5. Treatment of hepatitis C with new fixed dose combinations;Soriano;Expert Opin Pharmacother,2017

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Soluble inflammatory mediators identify HCV patients who may be cured with four weeks of antiviral treatment;Journal of Viral Hepatitis;2022-03-03

2. RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic;European Journal of Medicinal Chemistry;2021-03

3. Liver cT1 decreases following direct-acting antiviral therapy in patients with chronic hepatitis C virus;Abdominal Radiology;2020-11-28

4. Short‐duration treatment with the novel non‐nucleoside inhibitor CDI‐31244 plus sofosbuvir/velpatasvir for chronic hepatitis C: An open‐label study;Journal of Medical Virology;2020-11-22

5. JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study;Journal of Gastroenterology;2020-02-17